KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).

Frank A Sinicrope, Diana Segovia, Nalin Sharma, Steven R Alberts, Aaron Hardin, Thereasa Rich, Qian Shi

J Clin Oncol 44(15) 1401-1415

PMID41616224
PMCIDPMC12866954
DOI10.1200/JCO-25-02086
发表日期2026-01-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图;Figure 4::非 KM 图。
摘要

摘要

PURPOSE: Detection of molecular residual disease using circulating tumor DNA (ctDNA) may enable postoperative risk stratification and guide adjuvant therapy. We evaluated the prognostic value of a tissue-free, epigenomic ctDNA assay in patients with stage III colon cancer (CC) enrolled in a phase III adjuvant chemotherapy trial. METHODS: Plasma samples were collected after surgery and before adjuvant infusional fluorouracil, leucovorin, and oxaliplatin alone or combined with cetuximab. ctDNA was analyzed using a tissue-free assay; in ctDNA-positive patients, tumor fraction (TF) was quantified and genotyping was performed with a 739-gene panel. Associations with disease-free survival (DFS), time to recurrence (TTR), and overall survival (OS) were assessed using multivariable Cox models adjusted for covariates. RESULTS: Among 2,260 evaluable patients, 461 (20.4%) were ctDNA-positive with significantly higher detection in advanced T-/N-stage, high-grade, obstruction/perforation, and BRAFV600E tumors. At a median follow-up of 6.1 years, ctDNA positivity was independently associated with shorter TTR (hazard ratio [HR], 5.96 [95% CI, 5.11 to 6.96]), DFS (HR, 5.03 [95% CI, 4.36 to 5.81]), and OS (HR, 4.45 [95% CI, 3.76 to 5.27]; all P < .0001). The 5-year DFS was 27.7% (95% CI, 23.8 to 32.2) v 77.1% (95% CI, 75.1 to 79.1) in ctDNA-positive versus ctDNA-negative patients, and adverse prognostic impact was greater in lower T/N stage, low-risk, and dMMR subsets (interaction P = .0012-.041). Among ctDNA-positive patients, TF was nearly double in those who recurred or died (P = .0002) and stratified patients for TTR, DFS, and OS (all adjusted P < .002). Genotyping identified mutations in FLT1 (OR, 8.99) and PREX2 (OR, 7.73) genes that were most strongly associated with recurrence (P < .03). CONCLUSION: Evaluation of ctDNA in resected stage III CC using a tissue-free assay provided robust and independent prognostic value. Higher ctDNA burden, dMMR, and specific mutations defined poor prognostic groups among ctDNA-positive patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:5-year Disease-free Survival (A), Overall Survival (B) and Time-to-Recurrence (C) by postsurgical ctDNA status in patients with stage III colon cancer treated with FOLFOX-based adjuvant chemotherapy.
非 KM Figure
Figure 2:5-year patient DFS by postsurgical ctDNA status stratified by (A) T stage, (B) N stage, (C) clinical risk group, and (D) MMR status. (E), OS by postsurgical ctDNA status among patients with dMMR vs pMMR stage III colon cancer treated with FOLFOX-based adjuvant chemotherapy.
非 KM Figure
Figure 3:Forest plot displays hazard ratios (HRs) with 95% confidence intervals for DFS among patients with positive vs negative ctDNA status across multiple patient subgroups. Statistically significant associations are shown across all subgroups (all P <0.0001). With a Bonferroni adjustment to control for multiple comparisons, all of the subgroup analyses remained statistically significant (p-value < 0.0015).
非 KM Figure
Figure 4:Patient DFS (A), OS (B) and TTR (C) by quantitative ctDNA tumor fraction (TF) dichotomized at the median in ctDNA-positive patients with stage III colon cancer treated with FOLFOX-based adjuvant chemotherapy.
非 KM Figure